These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34493241)

  • 41. Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis.
    Taverna S; Flugy A; Saieva L; Kohn EC; Santoro A; Meraviglia S; De Leo G; Alessandro R
    Int J Cancer; 2012 May; 130(9):2033-43. PubMed ID: 21630268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. K562 cell-derived exosomes suppress the adhesive function of bone marrow mesenchymal stem cells via delivery of miR-711.
    Jiang YH; Liu J; Lin J; Li SQ; Xu YM; Min QH; Zhong QH; Sun F; Li J; You XH; Liao KL; Qin TY; Zhao C; Huang B; Wang XZ
    Biochem Biophys Res Commun; 2020 Jan; 521(3):584-589. PubMed ID: 31677790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
    Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
    Corrado C; Flugy AM; Taverna S; Raimondo S; Guggino G; Karmali R; De Leo G; Alessandro R
    PLoS One; 2012; 7(8):e42310. PubMed ID: 22879938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia.
    Bernardi S; Foroni C; Zanaglio C; Re F; Polverelli N; Turra A; Morello E; Farina M; Cattina F; Gandolfi L; Zollner T; Buttini EA; Malagola M; Russo D
    Int J Mol Med; 2019 Dec; 44(6):2133-2144. PubMed ID: 31638195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment.
    Huang J; Lu Z; Xiao Y; He B; Pan C; Zhou X; Xu N; Liu X
    Med Sci Monit; 2018 Feb; 24():727-735. PubMed ID: 29400343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nobiletin Promotes Megakaryocytic Differentiation through the MAPK/ERK-Dependent EGR1 Expression and Exerts Anti-Leukemic Effects in Human Chronic Myeloid Leukemia (CML) K562 Cells.
    Yen JH; Lin CY; Chuang CH; Chin HK; Wu MJ; Chen PY
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [An in vitro dendritic cells-induced T lymphocytes cytotoxicity study activated by thaw frozen K562 lysates antigen in chronic myeloid leukemia].
    Zuo XL; Zhou X; Liu XH; Chen F; He L; Meng J; Qu XJ
    Zhonghua Nei Ke Za Zhi; 2006 Dec; 45(12):1013-6. PubMed ID: 17327003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia.
    Xu H; Liu J; Shen N; Zhao Z; Cui J; Zhou S; Jiang L; Zhu X; Tang L; Liang H; Liu W; Zhu Z; Meng L; Zhu X
    Leuk Lymphoma; 2020 Jan; 61(1):128-137. PubMed ID: 31530212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
    Ramos TL; Sánchez-Abarca LI; López-Ruano G; Muntión S; Preciado S; Hernández-Ruano M; Rosado B; de las Heras N; Chillón MC; Hernández-Hernández Á; González M; Sánchez-Guijo F; Del Cañizo C
    Leuk Res; 2015 Aug; 39(8):921-4. PubMed ID: 26105049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
    Zhu XS; Lin ZY; Du J; Cao GX; Liu G
    Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling.
    Hao G; Zhai J; Jiang H; Zhang Y; Wu M; Qiu Y; Fan C; Yu L; Bai S; Sun L; Yang Z
    Biomed Pharmacother; 2020 Feb; 122():109677. PubMed ID: 31810012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells.
    Nakayama R; Kuroda J; Taniyama N; Yamamoto-Sugitani M; Wada S; Kiyota M; Mizutani S; Chinen Y; Matsumoto Y; Nagoshi H; Shimura Y; Kobayashi T; Horiike S; Sato K; Taniwaki M
    Leuk Res; 2014 Jan; 38(1):103-8. PubMed ID: 23953881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mesenchymal Stromal Cell-Derived Exosomes Affect mRNA Expression and Function of B-Lymphocytes.
    Khare D; Or R; Resnick I; Barkatz C; Almogi-Hazan O; Avni B
    Front Immunol; 2018; 9():3053. PubMed ID: 30622539
    [No Abstract]   [Full Text] [Related]  

  • 57. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells.
    Kobayashi CI; Takubo K; Kobayashi H; Nakamura-Ishizu A; Honda H; Kataoka K; Kumano K; Akiyama H; Sudo T; Kurokawa M; Suda T
    Blood; 2014 Apr; 123(16):2540-9. PubMed ID: 24574458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells.
    Domenis R; Cesselli D; Toffoletto B; Bourkoula E; Caponnetto F; Manini I; Beltrami AP; Ius T; Skrap M; Di Loreto C; Gri G
    PLoS One; 2017; 12(1):e0169932. PubMed ID: 28107450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.